189 related articles for article (PubMed ID: 18808308)
1. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation.
Tutka P
Expert Opin Investig Drugs; 2008 Oct; 17(10):1473-85. PubMed ID: 18808308
[TBL] [Abstract][Full Text] [Related]
2. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
3. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
[TBL] [Abstract][Full Text] [Related]
4. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
5. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2007 Jan; (1):CD006103. PubMed ID: 17253581
[TBL] [Abstract][Full Text] [Related]
6. An update on therapeutics for tobacco dependence.
Lancaster T; Stead L; Cahill K
Expert Opin Pharmacother; 2008 Jan; 9(1):15-22. PubMed ID: 18076335
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
8. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
9. Cytisine for smoking cessation: a research agenda.
Etter JF; Lukas RJ; Benowitz NL; West R; Dresler CM
Drug Alcohol Depend; 2008 Jan; 92(1-3):3-8. PubMed ID: 17825502
[TBL] [Abstract][Full Text] [Related]
10. [Drugs used to treat nicotine addiction].
Zieleń I; Sliwińska-Mossoń M; Milnerowicz H
Przegl Lek; 2012; 69(10):1098-102. PubMed ID: 23421099
[TBL] [Abstract][Full Text] [Related]
11. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of varenicline for smoking cessation.
Hays JT; Ebbert JO; Sood A
Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews.
Hartmann-Boyce J; Stead LF; Cahill K; Lancaster T
Addiction; 2013 Oct; 108(10):1711-21. PubMed ID: 23834141
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
Thomas D; Farrell M; McRobbie H; Tutka P; Petrie D; West R; Siahpush M; Gartner C; Walker N; Mendelsohn CP; Hall W; Paul C; Zwar N; Ferguson SG; Boland VC; Richmond R; Doran CM; Shakeshaft A; Mattick RP; Courtney RJ
Addiction; 2019 May; 114(5):923-933. PubMed ID: 30589984
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis.
De Santi O; Orellana M; Di Niro CA; Greco V
Addiction; 2024 Apr; 119(4):649-663. PubMed ID: 38161271
[TBL] [Abstract][Full Text] [Related]
16. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham CS; McMahon LR
Eur J Pharmacol; 2011 Mar; 654(1):47-52. PubMed ID: 21172344
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
19. Cytisine for smoking cessation: A systematic review and meta-analysis.
Ofori S; Lu C; Olasupo OO; Dennis BB; Fairbairn N; Devereaux PJ; Mbuagbaw L
Drug Alcohol Depend; 2023 Oct; 251():110936. PubMed ID: 37678096
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
